**ai-case-study**

## Overview and Origin

* *Name of company* * **Biofourmis**

* *When was the company incorporated?* * 2015 in Singapore 

* *Who are the founders of the company?* * Maulik Majmudar, Kuldeep Singh Rajput, and Mark Niu [^1]

* *How did the idea for the company (or project) come about?* * While completing his PhD in Singapore,company CEO, Kuldeep Singh Rajput dropped out to pursue AI technology [^1]
  
* *How is the company funded? How much funding have they received?* * As of 2022, Biofourmis has been funded $445 million through investors. Those investors include SoftBank Vision Fund 2, Openspace Ventures, Mass Mutual Ventures, Sequoia Capital and EDBI. In 2022, the company broke out of the unicorn status and into Series D investment with their partnership with General Atlantic [^2]

## Business Activities

* *What specific problem is the company or project trying to solve?* * The company is trying to bring hospital level care to patients in their own homes. This is implemented by combining AI programs and monitoring technology, in conjunction with FDA approved algorithms. The company is able to initiate virtual visits, along with personal care plans to prevent rehospitalization.In addition, Biofourmis helps people get involved in clinical trials by making user friendly tools and easy communication for participants. [^3] 

* *Who is the company's intended customer? Is there any information about the market size of this set of customers?* * The company is aiming to provide hospital level care to anyone who would like to seek medical attention reguardless of where they live. As per the company’s website, they have cared for 100,000 patients as of 2023 [^3]  

* *What solution does this company offer that their competitors do not or cannot offer? (What is the unfair advantage they utilize?)* * Biofourmis uses apps and easy to use biosensors to track a patient’s vital signs, as well as other biomarkers. This wearable technology provides data that is interpreted by an AI system to immediately assess a patient’s status. This AI platform takes the information and presents it to a medical team. This information is presented to medical professionals in a user-friendly format. It is also uploaded to a patient dashboard. This information can track acuity level and clinical goals for the patient. This AI tool can also adjust the level of care for the patient based on the changing conditions. [^3]

* *Which technologies are they currently using, and how are they implementing them? (This may take a little bit of sleuthing&mdash;you may want to search the company’s engineering blog or use sites like Stackshare to find this information.)* * Biofourmis uses several different technological aspects to build their AI system. The company uses an AI program called Biofourmis Biovitals. This is a system that monitors a patient’s physiological signs and compares it to their database. This information is then passed off to clinicians to make medical decisions. Along with the AI system, Biofourmis uses: BiovitalsHF, Rhythm Analytics, Biovitals Sentinel, Painfocus, Gaido and Biovitals Research. These are programs that the company uses in conjunction with the AI program. Those programs are monitoring software and cloud based software programs that can provide more data to the AI system.[^4] 

## Landscape

* *What field is the company in?* * Biotechnology

* *What have been the major trends and innovations of this field over the last 5&ndash;10 years?* * Over the past ten years there has been many new innovations in healthcare. As of 2022, the United Stated Food and Drug Administration (FDA) approved 91 medical devices with AI abilities [^5]. These devices range from cardiac arrhythmia tracking in Apple Watches and AI programed features in radiology devices to better highlight critical images. 
Advances in AI generated digital biomarkers have been used as an early detection for cancers and different cardiovascular diseases. AL has been used as a clinical decision support tool. This is very helpful to clinicians to be able to analyze historical data and determine a trend of the current date. Lastly, AI has been implemented in drug development. AI can use used to speed up the drug development process. For example, the medication *Olumiant* created by pharmaceutical company Eli Lilly used designed by AI [^5].

* *What are the other major companies in this field?* There are many new companies that are emerging in the healthcare field, the following are three successful ones. Butterfly Network is a company that designed a handheld medical image device that uses AI to make remote digital imagine possible.
Augmedix is a company that designed an AI program that listens in a doctor- patient conversations, makes medical notes and transfers the medical note into the patient chart. 
Artery is an AI healthcare company that uses AI to review radiology imaging and better detect health concerns [^6] 


## Results

* *What has been the business impact of this company so far?* Biofourmis received 300 million in funding through General Atlantic in 2022. In 2020 Biofournmis partnered with Brigham Women’s Hospital where they launched their remote patient monitoring system. In 2021, The company had their heart failure detection AI program BiovitalsHF approved by the FDA [^7]. Lastly, in as of February 2024, Biofournmis partnered with four pharamceditcal companies using their digital clinical trials program and their digital biomarkers technology [^8] 

* *What are some of the core metrics that companies in this field use to measure success? How is your company performing based on these metrics?* A metric for success in a company can be their revenue, Biofourmis’ revenue last year was 117.8 million. The company has been funded 463.6 million since it was established in 2015. The company currently holds 543 employees. There has been a drop in their employees since last year with 27% less staff [^1]. However, it is important to note that the company did grow substantially from 150 employees in 2020 to 500 in 2022. In addition, the company is valued at 1.3 billion as of 2023.
Buformins has some notable partnerships, those partnerships include Mayo Clinic, Discovery, Lorettto and MediClinic to name a few. The company’s technology is currently monitoring almost a hundrend thousand patients and states that with its technology there has been a 70% chance of hospitalization post discharge [^9]. Thus, Buformins is a successful start-up company that is continuing to grow in the biotechnology industry


* How is your company performing relative to competitors in the same field?

## Recommendations

* If you were to advise the company, what products or services would you suggest they offer? (This could be something that a competitor offers, or use your imagination!)

* Why do you think that offering this product or service would benefit the company?

* What technologies would this additional product or service utilize?

* Why are these technologies appropriate for your solution?
* ** References**
* [^1] https://growjo.com/company/Biofourmis.
* [^2] https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn status#:~:text=To%20date%2C%20Biofourmis%20has%20raised,Ventures%2C%20Sequoia%20Capital%20and%20EDBI.
* [^3] https://www.biofourmis.com/platform
* [^4] https://faimglobal.org/biofourmis/
* [^5] https://insights.omnia-health.com/technology/top-5-ai-driven-medical-innovations-united-states.
* [^6] https://medicalfuturist.com/top-artificial-intelligence-companies-in-healthcare/
* [^7] https://www.emarketer.com/content/biofourmis-bags-300m-mold-itself-digital-health-market-leader
* [^8] https://www.biofourmis.com/news-insights/biofourmis-secures-four-new-agreements-with-top-20-pharma-on-strength-of-platform-for-digital-clinical-trials-and-digital-biomarkers
* [^9] https://startuptalky.com/biofourmis-success-story/
